Study using nanoparticles to treat advanced pancreatic cancer – Chatbourgni

Clinical study conducted by the Institute of Oncology of Val-d-débronne (IOVH) Nanoparticles will be used to treat locally advanced pancreatic cancerFor which there is no effective treatment and which represents a major challenge for the European Union. 20% of all patients He suffers from this disease.

This study constitutes the final phase of the NoCanTher project, coordinated by IMDEA Nanoscience in Madrid, which includes the participation of professionals from different disciplines from eleven national and international centres, including Vall d’Hebron Hospital in Barcelona. In 2016, the international NoCanTher project was launched, and next September it will enter its final phase with the launch of the aforementioned clinical study led by VHIO and the project sponsor BioKeralty Research, for the treatment of locally advanced pancreatic cancer using magnetic nanoparticles.

This project is for people with pancreatic cancer with a A locally advanced tumor that has not spread but cannot be removed surgically. Those receiving palliative chemotherapy as the only treatment option. The ongoing clinical trial is based on results obtained in the pre-clinical phase of NoCanTher, in which the Vall d’Hebron Research Institute (VHIR) CIBBIM-Nanomedicine Targeting and Pharmacological Release group, led by Dr. Simo Schwartz Jr., played a very important role. An important role.

Project development magnetic iron particles Which, when exposed to an alternating magnetic field, generates heat – magnetic hyperthermia – which can be used to kill cancer cells. More responsive to standard chemotherapy Thus improving their efficiency, or even directly destroying these cells. To date, VHIR Hospital and Fuenlabrada Hospital (Madrid) have tested the utility of nanoparticles in animal models that were previously stimulated with pancreatic tumors or transplanted with patient-derived tumors.

The study showed that when nanoparticles are injected directly into the tumor, hyperthermia is produced It reduces the size of the tumor and also causes physical changes in the tumor that favor the entry of chemotherapy.. “This indicates a strong synergistic effect between nanoparticle-induced hyperthermia and pancreatic cancer chemotherapy,” Schwartz said. The nanoparticles heat up after applying an alternating magnetic field and enhance the effect of chemotherapy, which is then used to treat pancreatic cancer. administered simultaneously It is the standard treatment for these patients.

For her part, Dr. Teresa Macarola, Specialist Medical Oncologist at Vall d’Hebron Hospital, said: “We believe that with this new technique We can change the characteristics of the tumor and achieve disease control. locally. “This is a pilot trial, and one step closer to unlocking possible treatment options for patients with locally advanced pancreatic cancer for whom we cannot currently offer treatment,” he added. “Alternatives to Chemotherapy”.

In addition, the Vall d’Hebron researchers will take blood samples from patients to determine whether this treatment reduces the number of cancer cells circulating in the blood, particularly cancer stem cells that are able to produce new cancer cells and form metastases.

The researchers demonstrated that this approach is based on ferromagnetic iron oxide nanoparticles It is allowed to apply heat only to the area where the tumor is. Pancreatic tumor, without any consequences for the healthy tissue around the tumor. In this study, a magnetic field generator (NTT generator), which has been specifically designed and built for the local generation of thermal energy within the tumor, will be used.

The NoCanTher project is coordinated by IMDEA Nanoscience (Madrid) and includes participation: BioKeralty Research Institute (Vitoria); Imyopharma (London); Chemisil (Berlin); University Hospital (Jena, Germany); resonance circuits (London); Vall débrune Institute for Research (VHIR) and Vall débrune Institute of Oncology (VHIO) (Barcelona); Trinity College (Dublin); University of Paris Diderot (Paris); University Hospital Fuenlabrada (Madrid), benefiting from the funding of the Horizon 2020 programme.

#Study #nanoparticles #treat #advanced #pancreatic #cancer #Chatbourgni

Leave a Comment

Your email address will not be published.